Opinion|Videos|January 15, 2026
Reflecting on the Trial Landscape in GCA and History of Approved Agents
Advertisement
Episodes in this series
This video covers the following questions:
- Please provide an overview of clinical trial data for FDA-approved targeted therapies for GCA (such as tocilizumab and upadacitinib). (
Stone 2017 ) (Blockmans 2025 )
Advertisement
Related to this article
AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.
Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Mirikizumab Deep Remission in Crohn’s Disease, With Stefan Schreiber, MD
3
Reaching Comprehensive Disease Control in UC, With Stefan Schreiber, MD
4
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
5